Published by the IC
nternational M I
yeloma FT
oundation
IN
Special Edition: G
ASCO 2011
SQ2/2011
Novel Therapies Issue
The International Myeloma Foundation (IMF) presents this issue of Citings, our premiere publication featuring
the most up-to-date information on myeloma treatment and supportive care, focused on the novel therapies
currently under study and in use. This edition corresponds with presentations (oral and poster) and abstracts from
the American Society of Clinical Oncology (ASCO) annual meeting, to be held June 3-7, 2011 in Chicago, Illinois.
It is our hope that CITINGS will be a valuable tool in keeping you informed on the latest developments in myeloma
treatment. Please feel free to contact us at (800) 452-CURE (2873) or visit us on the web at myeloma.org.
Susie Novis, President, IMF
American Society of Clinical Oncology
Presentations 2011
Saturday, June 4th
Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ),
lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma
(R/R MM).
M. Wang, W. Bensinger, T. Martin, M. Alsina, D.S.D. Siegel, N.Y. Gabrail, P. Hari, S. Singhal, R.A. Vescio,
S.E. Assouline, L.A. Kunkel, M. Val one, A. Wong, R. Niesvizky
J Clin Oncol 29: 2011 (suppl; abstr 8025)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8025
Type: Poster Discussion Session
Time: 8:00 AM - 12:00 PM
Location: McCormick Place E450b
Discussion Time: 12:00 PM - 1:00 PM
Location: McCormick Place E354a
This phase II study further evaluates safety and activity of carfilzomib in combination with lenalidomide and
low-dose dexamethasone in relapsed/refractory myeloma patients. (CRd in R/R MM pts.) The authors find that this
combination is well-tolerated in patients previously treated with bortezomib, lenalidomide and/or thalidomide;
overall response rate was 78% and prolonged administration was possible (1423 mo.) with no new or overlapping
toxicities.
myeloma.org
(800) 452 - CURE (2873)
Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation
(MEL200) in newly diagnosed multiple myeloma (MM) patients: A phase III trial.
M. Boccadoro, F. Caval o, A. Nagler, D. Ben Yehuda, P. Omedč, M. Caval i, A. Levi, C. Crippa, A. Siniscalchi,
P. Brasca, A.M. Carel a, B.A. Zanetti, F. Patriarca, S. Pezzati, V. Montefusco, A. Stanevsky, B. Lupo, T. Caravita,
F. Di Raimondo, A.P.Palumbo
J Clin Oncol 29: 2011 (suppl; abstr 8020)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8020
Type: Poster Discussion Session
Time: 8:00 AM - 12:00 PM
Location: McCormick Place E450b
Discussion Time: 12:00 PM - 1:00 PM
Location: McCormick Place E354a
This is the first prospective randomized study comparing conventional chemotherapy plus novel agents
melphalan/prednisone/lenalidomide (MPR) with tandem high-dose melphalan (MEL200) and autologous stem-cell
transplantation (ASCT) in newly diagnosed myeloma patients. The authors find that MEL200 is superior to MPR
for progression-free survival (PFS), although toxicities are significantly higher; this is the first report showing a
PFS advantage for ASCT in comparison with combinations including novel agents. At present overall survival is not
significantly different in the two groups.
Phase II study of carfilzomib (CFZ) in combination with current agents for relapsed and refractory multiple
myeloma (RRMM).
J. Szymonifka, S.Z. Usmani, R. Sexton, S. Panozzo, B.P. Nair, S. Waheed, Y. Alsayed, J. Crowley, B. Barlogie
J Clin Oncol 29: 2011 (suppl; abstr 8028)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8028
Type: Poster Discussion Session
Time: Saturday June 4, 8:00 AM - 12:00 PM
Location: McCormick Place E450b
Discussion Time: 12:00 PM - 1:00 PM
Location: McCormick Place E354a
This phase II study evaluates the efficacy of carfilzomib (CFZ) in the relapsed and refractory myeloma patient
population. The authors find that in this far advanced patient population, CFZ seemed to have single agent activity;
an improvement in disease was seen in about half the patients, especially in combination with other agents, such as
bortezomib, thalidomide and lenalidomide.
myeloma.org
(800) 452 - CURE (2873)
Sunday, June 5th
Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma:
A randomized phase II study.
P.G.G. Richardson, P. Moreau, A.J. Jakubowiak, T. Facon, S. Jagannath, R. Vij, D.E. Reece, D. White,
M. Raab, L. Benboubker, J. Rossi, C. Tsao, T. Parli, D. M. Berman, A. K. Singhal, S. Lonial
J Clin Oncol 29: 2011 (suppl; abstr 8014)
Myeloma
Abstract No.: 8014
Type: Oral Abstract Session
Time: 9:30 AM - 12:30 PM
Location: McCormick Place E354a
In this phase II study, previously treated myeloma patients are randomized to elotuzumab 10 or 20 mg/kg IV
(days 1, 8, 15, and 22 every 28 days in first 2 cycles and days 1 and 15 of subsequent cycles), lenalidomide
25 mg PO (days 121) and dexamethasone 40 mg PO (weekly). The authors find that elotuzumab plus lenalidomide/
dexamethasone is generally well tolerated with manageable toxicity and resulted in a high overall response rate
in patients with previously-treated myeloma; further clinical study of this combination using 10 mg/kg elotuzumab
is warranted.
Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide
in first-line treatment of multiple myeloma (MM).
A.C. Rossi, T.M. Mark, D. Jayabalan, P.J. Christos, F. Zafar, K. Pekle, T. Shore, R.N. Pearse, J. Leonard,
S. Chen-Kiang, M. Coleman, R. Niesvizky
J Clin Oncol 29: 2011 (suppl; abstr 8008)
Myeloma
Abstract No.: 8008
Type: Oral Abstract Session
Time: 9:30 AM - 12:30 PM
Location: McCormick Place E354a
In this study, the authors find that clarithromycin, lenalidomide and dexamethasone is a highly effective regimen
in newly diagnosed myeloma. In these treatment-naďve patients, no cases of secondary MDS/AML are seen.
Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination
followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts)
age 65 or older.
A.P. Palumbo, M. Delforge, J. Catalano, R. Hájek, M. Kropff, M.T. Petrucci, Z. Yu, J.M. Mei,
M.A. Dimopoulos
J Clin Oncol 29: 2011 (suppl; abstr 8007)
Myeloma
Abstract No.: 8007
Type: Oral Abstract Session
Time: 9:30 AM - 12:30 PM
Location: McCormick Place E354a
Myeloma patients have an 8-10 fold higher risk of developing acute myeloid leukemia (AML) than the general
population. In this study, the authors observe an imbalance of AML incidence melphalan-prednisone-lenalidomide
(MPR)/MPR-followed by lenalidomide maintenance patients, as compared to melphalan-prednisone alone, but
incidence is low (0.7% vs 0%) and associated with complex baseline cytogenetics. Solid tumor incidence rates are
low and similar for all arms, and at present, the secondary primary malignancy (SPM) risk is similar to that reported
in other studies. Longer follow-up is needed to definitively assess the risk of SPM in newly diagnosed myeloma
patients receiving lenalidomide and alkylating agents.
myeloma.org
(800) 452 - CURE (2873)
Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma
(RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010.
M.A. Dimopoulos, R.Z. Orlowski, R. Niesvizky, S. Lonial, N.A. Brandenburg, D.M. Weber
J Clin Oncol 29: 2011 (suppl; abstr 8009)
Myeloma
Abstract No.: 8009
Type: Oral Abstract Session
Time: 9:30 AM - 12:30 PM
Location: McCormick Place E354a
This post hoc analysis is based on pooled MM-009/010 data and finds that, overall, the low number and type of
secondary primary malignancies do not change the benefit-risk profile for lenalidomide in relapsed/refractory
myeloma patients.
Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and
dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma
(MM).
J.G. Berdeja, S. Ailawadhi, S.D. Weitman, S. Zildjian, J.J. O'Leary, J. O'Keeffe, R. Guild, K. Whiteman,
A.A.A. Chanan-Khan
J Clin Oncol 29: 2011 (suppl; abstr 8013)
Myeloma
Abstract No.: 8013
Type: Oral Abstract Session
Time: 9:30 AM - 12:30 PM
Location: McCormick Place E354a
The authors seek to determine the maximum tolerated dose (MTD), dose limiting toxicity and activity
of lorvotuzumab mertansine (LM) in combination with fixed doses of lenalidomide and dexamethasone;
They conclude that LM in combination with Len and Dex has shown objective evidence of clinical activity
with an acceptable safety profile; the dose-escalation portion of the study is open to enrollment for further
exploration of the MTD.
Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously
treated multiple myeloma.
J Clin Oncol 29: 2011 (suppl; abstr 8012)
N.S. Raje, R.J. Hohl, E.A. Faber, P.G.G. Richardson, A. Forero-Torres, G. J. Schil er, A. D. Cohen,
S.P. Carpenter, D. Cronier, M. Pashkevich, J. Wooldridge, K.C. Anderson
Myeloma
Abstract No.: 8012
Type: Oral Abstract Session
Time: 9:30 AM - 12:30 PM
Location: McCormick Place E354a
A combination of LY2127399 (LY) and bortezomib is evaluated in this phase I dose escalation study. The authors
ultimately select an 100 mg dose of LY for further study with bortezomib based on assessed pharmacokinetics.
They find that the safety profile is similar to bortezomib alone, and an overall response rate of 55%, despite prior
bortezomib (65%). They also find that the percent change in k-l SFLC difference correlates strongly with response.
They conclude that this data supports further evaluation of LY in combination with bortezomib.
myeloma.org
(800) 452 - CURE (2873)
Monday, June 6th
PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in
combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.
J.F. San Miguel, S. Lonial, V. Hungria, P. Moreau, H. Einsele, J.H. Lee, S. Yoon, P. Corradini,
W. W. Jedrzejczak, D. C. Tan, K. Yong, A. Guenther, M.M. Wroclawska-Swacha, H.J. Weber, P.M. Bourquelot,
P.G.G. Richardson
J Clin Oncol 29: 2011 (suppl; abstr TPS227)
Trials in Progress Poster Session
Abstract No.: TPS227
Type: Trials in Progress Poster Session
Time: 8:00 AM - 12:00 PM
Location: McCormick Place Hall A
The authors initiate a global, randomized, double-blind, phase III study of panobinostat (PAN) + bortezomib +
dexamethasone (DEX) vs. placebo (PBO) + bortezomib + DEX to determine if PAN can improve outcomes in
patients with relapsed myeloma. As of Jan 31, 2011, 270 patients were randomized.
Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib,
on bone lysis and tumor load in a physiologic model of myeloma.
J. Endel , C. Samuelsson, R. Boxhammer, S. Strauss, S. Steidl
J Clin Oncol 29: 2011 (suppl; abstr 8078)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8078
Type: General Poster Session
Time: 1:00 PM - 5:00 PM
Location: McCormick Place Hall A
The authors evaluate bortezomib and lenalidomide for their ability to enhance the cytotoxicity of MOR202 in vitro
and in vivo. They find that the cytotoxic activity of MOR202 on myeloma cells is enhanced by bortezomib and
lenalidomide by different mechanisms, and that inhibition of myeloma-mediated bone lysis and tumor load in vivo
is enhanced by both compounds in a synergistic manner with MOR202.
Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly
diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results
of an ongoing clinical study.
N.C. Munshi, S. Lee, S. Kambhampati, A. Mohiuddin, M.G. Rose, C. Behler, A. Han, Y.A. Efebera,
A. Houranieh, M.T. Brophy, A. Zimelman, R.H. Prabhala, T. Grady, C.E. Klein, P. Mehta, T.G. Hayes,
G.D. Roodman, A. Lichtenstein
J Clin Oncol 29: 2011 (suppl; abstr 8074)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8074
Type: General Poster Session
Time: 1:00 PM - 5:00 PM
Location: McCormick Place Hall A
This phase II multi-center single-arm study investigates the efficacy and safety of a weekly bortezomib regimen. The
authors' preliminary results point to the effectiveness and tolerability of the once a week bortezomib regimen, even
in older myeloma patients with significant co-morbidities.
myeloma.org
(800) 452 - CURE (2873)
Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma:
A phase I/II trial.
J.R. Berenson, O. Yel in, A. Bessudo, R. Boccia, S. Noga, D. Gravenor, D. Patel-Donnel y, R.S. Siegel,
T. Kewalramani, E.J. Gorak, R. Swift, D. Bensen-Kennedy
J Clin Oncol 29: 2011 (suppl; abstr 8070)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8070
Type: General Poster Session
Time: 1:00 PM - 5:00 PM
Location: McCormick Place Hall A
This open-label, phase I/II study assesses the efficacy/safety of bendamustine plus bortezomib in relapsed/refractory
myeloma. The authors find that bendamustine 90 mg/m2 plus bortezomib 1.0 mg/m2 is well tolerated with
promising efficacy in this heavily pretreated population.
Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and
maintenance in newly diagnosed multiple myeloma (MM) patients ineligible for transplant in the
phase IIIb UPFRONT study.
R. Niesvizky, I. W. Flinn, R. M. Rifkin, N. Gabrail, V. Charu, Y. Gaffar, R. Neuwirth, D. Corzo, J. Reeves
J Clin Oncol 29: 2011 (suppl; abstr 8072)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8072
Type: General Poster Session
Time: 1:00 PM - 5:00 PM
Location: McCormick Place Hall A
This multicenter, phase IIIb study compares the efficacy and safety of three bortezomib-based induction regimens
bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone and bortezomib-melphalan-prednisone
followed by weekly bortezomib maintenance, for newly diagnosed myeloma patients ineligible for HDT-SCT. The
results suggest that bortezomib-containing regimens are active across various patient subgroups including gender,
race, co-morbidity status, and ISS stage.
The impact of frontline risk-adapted strategy on the overall survival (OS) of patients with newly diagnosed
multiple myeloma (MM): A population study in Singapore.
D. C. Tan, K. H. Ong, L. P. Koh, S. S. Wong, M. T. Khin, L. H. Lee, Y. T. Goh, W. J. Chng
J Clin Oncol 29: 2011 (suppl; abstr 8081)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8081
Type: General Poster Session
Time: 1:00 PM - 5:00 PM
Location: McCormick Place Hall A
The authors evaluate the survival data of myeloma patients managed in Singapore, overall, and with respect to
treatment eras before and after the incorporation of bortezomib as frontline therapy for high-risk myeloma. Their
findings suggest that bortezomib in frontline combination (rather than sequential use) may be better able to
overcome adverse risk factors; upfront risk-adapted strateg y may be vital for optimizing healthcare resources.
myeloma.org
(800) 452 - CURE (2873)
Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts):
Analysis of pooled data.
B.G.M. Durie, G. Morgan, J.F. San Miguel, R.Z. Orlowski, S. Lonial, R. Niesvizky, Z. Yu, K.C. Anderson
J Clin Oncol 29: 2011 (suppl; abstr 8086)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8086
Type: General Poster Session
Time: 1:00 PM - 5:00 PM
Location: McCormick Place Hall A
The authors compare incidence of second primary malignancies (SPM) observed in lenalidomide studies with
expected background incidence of all invasive cancers as reported from the U.S. Surveillance, Epidemiolog y,
and End Results (SEER) Cancer Registries, 2003-2007. They find that treatment with lenalidomide-based therapy
for relapsed/refractory myeloma, including treatment durations of 24 mos, shows clear clinical benefit and no
significant increase in rate of SPM compared to incidence rates for invasive malignancies reported by SEER.
Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed
or refractory multiple myeloma.
S. Lonial, R. Vij, T. Facon, P. Moreau, X. Leleu, A. Mazumder, J.L. Kaufman, C. Westland, C. Tsao,
A.K. Singhal, S. Jagannath
J Clin Oncol 29: 2011 (suppl; abstr 8076)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8076
Type: General Poster Session
Time: 1:00 PM - 5:00 PM
Location: McCormick Place Hall A
This phase I study assesses the maximum tolerated dose (MTD), safety, and efficacy of elotuzumab with
lenalidomide plus low-dose dexamethasone in patients with relapsed/refractory myeloma. During the dose
escalation phase, there were no dose limiting toxicities, and the MTD was not reached. A phase II trial of
elotuzumab (10 vs. 20 mg/kg) with lenalidomide/dexamethasone is ongoing.
A phase Ib study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory
multiple myeloma.
J.F. San Miguel, P.G.G. Richardson, O. Sezer, A. Guenther, D. S. D. Siegel, J. Bladé, R. LeBlanc,
H.J. Sutherland, M. Mateos, M. Gramatzki, K.M. Hazel , B. Bengoudifa, P.M. Bourquelot, K.C. Anderson
J Clin Oncol 29: 2011 (suppl; abstr 8075)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8075
Type: General Poster Session
Time: 1:00 PM - 5:00 PM
Location: McCormick Place Hall A
This phase Ib study finds that the combination of panobinostat and bortezomib has a predictable and manageable
safety profile with promising activity in advanced myeloma, including those patients with bortezomib-refractory
myeloma.
myeloma.org
(800) 452 - CURE (2873)
A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide
(DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM).
O. Yel in, J.R. Berenson, T. Kazamel, C. Chen, A. Cartmel, T.B.S. Woliver, M.S. Flam, E.N. Bravin, Y. Nassir,
R.A. Vescio, R. Swift
J Clin Oncol 29: 2011 (suppl; abstr 8082)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8082
Type: General Poster Session
Time: 1:00 PM - 5:00 PM
Location: McCormick Place Hall A
This ongoing, single-arm, multi center phase II study for relapsed/refractory myeloma patients finds that the
peg ylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide regimen is a well-tolerated
treatment that produces high response rates for heavily pretreated myeloma patients with relapsed/refractory
disease.
Single-agent lenalidomide for newly diagnosed myeloma with on-demand dexamethasone: A phase II trial.
F. Buadi, M. Lacy, A. Dispenzieri, B. LaPlant, K. M. Laumann, G.S. Nowakowski, S. R. Hayman,
K. Detweiler Short, D. Dingli, M.A. Gertz, P. R. Greipp, J. A. Lust, T.E. Witzig, S.R. Zeldenrust, S.J. Russel ,
V. Rajkumar, S. Kumar
J Clin Oncol 29: 2011 (suppl; abstr 8080)
Lymphoma and Plasma Cell Disorders
Abstract No.: 8080
Type: General Poster Session
Time: 1:00 PM - 5:00 PM
Location: McCormick Place Hall A
The authors design a trial of single agent lenalidomide, with dexamethasone added based on response, for newly
diagnosed myeloma patients. They find that this is a feasible strateg y that will allow avoidance of dexamethasone-
related side effects, especially in patients where other coexisting illnesses make steroid side effects difficult to
manage; the responses are slower than seen with lenalidomide with dexamethasone, and neutropenia and fatigue
are the main toxicities.
Abstract Only
Are out-of-pocket payments for oral oncologic therapies too high? Updated results from a U.S. claims
data analysis.
M.L. Raborn, E.M. Pel etier, D.B. Smith, C.M. Reyes
J Clin Oncol 29: 2011 (suppl; abstr e16512)
Abstract No.: e16512
This study evaluated out-of-pocket payments (OOPP) for oral oncologics (including lenalidomide and thalidomide)
in U.S. managed care plans. The authors find that OOPP in the U.S. differ among oral oncologic options; as costs
for therapy become a greater part of treatment decisions, an understanding of patient cost burden will be critical in
informing choices.
myeloma.org
(800) 452 - CURE (2873)
Bortezomib (BZB)-associated adverse events (AE) in patients with multiple myeloma (MM).
L. Katragadda, N. Sanathkumar, M. Veeraputhiran, A. Restrepo, S. Haider, J. Muzaffar, B. Barlogie, E.J. Anaissie
J Clin Oncol 29: 2011 (suppl; abstr e18565)
Abstract No.: e18565
The authors conduct a retrospective case control study of 5 patients, with patients serving as their own control.
They find that high dose bortezomib therapy is associated with otherwise unexplained, but transient, orthostatic
hypotension, pyrexia and severe diarrhea and constipation. These findings are classically observed in autonomic
nervous system (ANS) disorders, suggesting that some bortezomib-related adverse events may be caused by transient
ANS dysfunction.
Cost differences among treatment options for patients with refractory myeloma previously treated
with high-dose chemotherapy and autologous stem-cell transplantation: An analysis from the U.S. and
Swiss perspectives.
P.R. Blank, R. Levin, B.C. Pestalozzi, T.D. Szucs
J Clin Oncol 29: 2011 (suppl; abstr e16569)
Abstract No.: e16569
The authors study costs of various treatment options (including use of thalidomide, lenalidomide and bortezomib)
for patients with refractory myeloma previously treated with high-dose chemotherapy and autologous stem-cell
transplantation. The study finds that costs for refractory myeloma patients vary considerably for the various
treatment regimens, especially when overall response rates are taken into account. Analyses of drug costs provide
important information for clinicians, patients, and health policy makers involved in treatment decisions.
The effect of selective inhibition of HDAC6 with ACY1215 on bortezomib activity in multiple myeloma
(MM).
L. Santo, T. Hideshima, A.L. Kung, M. Yang, D. Tamang, M. Jarpe, J.H. van Duzer, R. Mazitschek, D. Cirstea,
K. Patel, J. Tseng, S. Rodig, S. Pozzi, J. Bradner, K.C. Anderson, S.S. Jones, N.S. Raje
J Clin Oncol 29: 2011 (suppl; abstr e18569)
Abstract No.: e18569
The authors investigate the preclinical activity of an HDAC6 selective inhibitor ACY1215 in myeloma, alone and
in combination with bortezomib. They conclude that their results provide the rationale for clinical evaluation of
ACY1215, alone and together with bortezomib, in the treatment of myeloma.
Improvement of painful bortezomib-induced peripheral neuropathy following acupuncture treatment in a
case series of patients with multiple myeloma.
T. Bao, M. Medeiros, R. Zhang, L. Lao, A. Z. Badros
J Clin Oncol 29: 2011 (suppl; abstr e19569)
Abstract No.: e19569
The authors report a retrospective case series of five myeloma patients using acupuncture to relieve painful
bortezomib-induced peripheral neuropathy. They conclude that acupuncture is a viable option for patients
experiencing this side effect.
myeloma.org
(800) 452 - CURE (2873)
Lenalidomide plus low-dose dexamethasone compared with thalidomide plus low-dose dexamethasone
in the treatment of newly diagnosed multiple myeloma: Results of an ongoing prospective randomized
phase III trial.
A. Mookerjee, A. Sharma, R. Gupta, L. Kumar
J Clin Oncol 29: 2011 (suppl; abstr e18572)
Abstract No.: e18572
The authors compare the efficacy and safety and assess quality of life (QOL) of both thalidomide and lenalidomide
in combination with dexamethasone. They find that for newly diagnosed myeloma patients, induction treatment
with lenalidomide-dexamethasone is associated with better toxicity profile and improved QOL compared to
thalidomide-dexamethasone.
The potential of the human CD38-specific antibody daratumumab to improve the antimyeloma effect
of novel multidrug therapies including patients refractory to lenalidomide or bortezomib.
T. Mutis, M. de Weers, M.S. van der Veer, B. v. Kessel, J.M. Bakker, S. Wittebol, P. Parren, H.M. Lokhorst
J Clin Oncol 29: 2011 (suppl; abstr e18571)
Abstract No.: e18571
The authors explore the possibility of combining novel myeloma therapeutics with daratumumab (DARA). Their
results illustrate that treatment of myeloma with DARA in combination with novel multidrug therapies, particularly
lenalidomide+bortezomib, shows great promise.
A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and
dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).
P. Moreau, A.P. Palumbo, A. K. Stewart, V. Rajkumar, A. J. Jakubowiak, K. Halka, S. Goranov,
H. Bumbea, K.B. Pendergrass, A. Lupu, A. Dimopoulos, A.O. Rocafiguera, J.G. Gandhi, G. Mihaylov,
T. Masszi, J. Matous, G. Fonseca, R. Bryce, D.S.D. Siegel
J Clin Oncol 29: 2011 (suppl; abstr TPS225)
Abstract No.: TPS225
This phase 3, randomized, open-label, multicenter study compares carfilzomib-lenalidomide to lenalidomide alone
in the treatment of patients with relapsed myeloma. Enrollment was initiated in July 2010, with a final accrual goal
of 700 patients.
myeloma.org
(800) 452 - CURE (2873)
(800)452-CURE (2873)
myeloma.org